Evaluation of different immunoassays for the detection of antiphospholipid antibodies: Report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies

Forastiero, Ricardo; Papalardo, Elizabeth; Watkins, Michael; Nguyen, Ha Cam Thuy; Quirbach, C.; Jaskal, K.; Kast, M.; Teodorescu, Marius; Lakos, Gabriella; Binder, Walter L.; Shums, Zakera; Nelson, V.; Norman, Gary L.; Puig, Jaime; Cox, Angela; Vandam, W.; Hardy, Jules; Pierangeli, Silvia S.

doi:10.1016/j.cca.2013.11.009

Cited by 32 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Automation can also reduce intra-and inter-laboratory variability and improve the reproducibility of the results [22]. Some studies have been performed since CLIA first became available to compare this new technology with ELISA testing, which is more commonly used to detect aCL and anti-β2GPI antibodies [23][24][25][26][27][28][29]. These comparison studies were, however, carried out using different CLIA instruments and various ELISA techniques (homemade methods and various commercial kits).…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method

Meneghel

Ruffatti

Gavasso

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

“…In particular, chemiluminescence immunoassay (CLIA) has been available for aCL and anti-β2GPI antibody detection since 2010 [23]. Studies comparing the performance of CLIA with that of ELISA have been performed in heterogeneous groups of patients and have produced divergent results [23][24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 98%

The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method

Meneghel

Ruffatti

Gavasso

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…As a result, the variability in anti-cardiolipin antibody (aCL) measurement that characterized first-generation assays [24] has been reduced. The availability of a cardiolipin calibrator from APL Laboratories [25] has also improved agreement in the measurement of these antibodies [26].…”

Section: Methods Used To Determine the Presence Of Aplmentioning

confidence: 99%

“…There was optimism that the positive results seen in the presence of infections and other inflammatory conditions would decrease when cardiolipin was not used as an antigen in the assays [42,43]. Immunoassays that directly measure antibodies to β2GPI have improved the specificity of aPL testing and also permitted the use of a better defined recombinant target, which is now widely utilized in commercial assays [26]. However, the elimination of cardiolipin antigen as a target in immunoassays does not preclude the possibility of aPL resulting from infections.…”

Section: Transient Versus Persistent Antibodiesmentioning

confidence: 98%

See 1 more Smart Citation

Anti-phospholipid Antibodies and Smoking: An Overview

Binder

Litwin

2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Antiphospholipid syndrome is characterized by the presence of antiphospholipid antibodies, specifically lupus anticoagulant, anticardiolipin antibodies, and anti-β2 glycoprotein-I antibodies. Antiphospholipid syndrome can occur on its own or in association with other autoimmune diseases, most commonly systemic lupus erythematosus (SLE). A connection between cigarette smoking and anti-phospholipid antibodies (aPL) was first reported in the late1980s. Systemic lupus erythematosus patients with aPL are more likely to be smokers than those without aPL. These patients have a particularly high frequency of vascular events. Recently, a potential link between periodontitis, tobacco, and aPL has been proposed. Research has also suggested that periodontitis and Porphyromonas gingivalis infection are associated with citrullination through the action of peptidylarginine deiminase. A strong correlation between smoking and the presence of citrillunated autoantibodies, which are characteristic of rheumatoid arthritis, has also been observed. While many studies have investigated possible links between infection and aPL in patients with autoimmune diseases, the association of smoking with aPL has not been systematically examined. The fact that both aPL and tobacco are risk factors for thrombosis has complicated efforts to evaluate these factors separately. Also, there has been great variability in measurement techniques, and laboratories lack routine methods for differentiating transient and persistent aPL; both of these factors can make interpretation of autoantibody results quite challenging. This review summarizes the clinical evidence supporting a posited link between aPL and smoking, both in patients with a systemic autoimmune disease and in patients with other medical conditions.

show abstract

Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests

Bertolaccini

Amengual

Artim-Eser

et al. 2017

Antiphospholipid Syndrome

View full text Add to dashboard Cite

Evaluation of different immunoassays for the detection of antiphospholipid antibodies: Report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies

Cited by 32 publications

References 22 publications

The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method

The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method

Anti-phospholipid Antibodies and Smoking: An Overview

Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests

Contact Info

Product

Resources

About